Kornitzer Capital Management Inc. KS Invests $5.66 Million in Masimo Co. (NASDAQ:MASI)

Kornitzer Capital Management Inc. KS purchased a new position in shares of Masimo Co. (NASDAQ:MASI) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 38,050 shares of the medical equipment provider’s stock, valued at approximately $5,661,000. Kornitzer Capital Management Inc. KS owned about 0.07% of Masimo as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Dorsey Wright & Associates grew its position in Masimo by 1.0% in the 3rd quarter. Dorsey Wright & Associates now owns 25,947 shares of the medical equipment provider’s stock valued at $3,861,000 after buying an additional 247 shares in the last quarter. California Public Employees Retirement System grew its position in Masimo by 38.7% in the 3rd quarter. California Public Employees Retirement System now owns 116,074 shares of the medical equipment provider’s stock valued at $17,271,000 after buying an additional 32,407 shares in the last quarter. Handelsbanken Fonder AB grew its position in Masimo by 69.7% in the 3rd quarter. Handelsbanken Fonder AB now owns 226,500 shares of the medical equipment provider’s stock valued at $33,701,000 after buying an additional 93,000 shares in the last quarter. Commonwealth Equity Services LLC grew its position in Masimo by 4.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 5,098 shares of the medical equipment provider’s stock valued at $758,000 after buying an additional 208 shares in the last quarter. Finally, BB&T Securities LLC bought a new position in Masimo in the 3rd quarter valued at about $357,000. Institutional investors and hedge funds own 82.75% of the company’s stock.

In other Masimo news, Director Sanford Fitch sold 7,000 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $150.39, for a total transaction of $1,052,730.00. Following the transaction, the director now owns 44,245 shares in the company, valued at $6,654,005.55. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Micah W. Young sold 12,087 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $150.02, for a total value of $1,813,291.74. Following the transaction, the chief financial officer now owns 10,000 shares in the company, valued at approximately $1,500,200. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,600 shares of company stock worth $6,094,362. Insiders own 11.50% of the company’s stock.

Shares of NASDAQ:MASI traded up $1.57 during trading hours on Friday, hitting $142.95. 310,600 shares of the company’s stock traded hands, compared to its average volume of 391,190. The company has a market cap of $7.58 billion, a price-to-earnings ratio of 47.18, a price-to-earnings-growth ratio of 1.95 and a beta of 1.14. The company’s fifty day simple moving average is $146.39 and its two-hundred day simple moving average is $145.98. Masimo Co. has a 52 week low of $98.23 and a 52 week high of $160.25.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.03. The firm had revenue of $229.01 million for the quarter, compared to analyst estimates of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.71 earnings per share. Analysts expect that Masimo Co. will post 3.17 EPS for the current fiscal year.

A number of equities analysts recently issued reports on the stock. UBS Group increased their target price on shares of Masimo from $172.00 to $180.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. BidaskClub lowered shares of Masimo from a “hold” rating to a “sell” rating in a research report on Friday. Stifel Nicolaus raised their price objective on shares of Masimo from $165.00 to $170.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. BTIG Research restated a “hold” rating on shares of Masimo in a research report on Thursday, August 1st. Finally, ValuEngine lowered shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $159.25.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: Why is cost of goods sold important?

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply